Early evidence links some Alzheimer’s Disease medications to small cognitive gains in children with autism and low IQ, ...
Proceedings of the National Academy of Sciences of the United States of America, Vol. 111, No. 23 (June 10, 2014), pp. 8649-8654 (6 pages) Ketamine is an NMDA receptor (NMDAR) antagonist that elicits ...
A comparative analysis of inpatient Do Not Resuscitate (DNR) forms used at National Cancer Institute-designated cancer centers (NCICC) No significant financial relationships to disclose. This is an ...
Memantine HCl 7mg, 14mg, 21mg, 28mg; ext-rel caps. Memantine is postulated to exert its therapeutic effect through its action as a low to moderate affinity uncompetitive (open-channel) N-methyl ...
A new Cochrane review casts doubt on the value of ketamine and other N-methyl-D-aspartate (NMDA) receptor agonists to relieve chronic noncancer pain. “Clinicians should know that there is currently no ...
Alzheimer's disease destroys brain cells and their connections (called synapses), causing memory loss and other cognitive problems that disrupt work, hobbies and daily life. Symptoms can be alleviated ...
Drugs that act on NMDA (N-methyl-D-aspartate) receptors, which are essential for learning, memory and moment-by-moment consciousness, are key for treating neuropsychiatric disorders. These drugs were ...
Despite growing off-label use, ketamine and related NMDA blockers show no reliable evidence of easing chronic pain, highlighting the urgent need for safer and more effective treatments. Review: ...
GluN3A-deficient mice display all aspects of Alzheimer's neurodegeneration. In the context of recent debate over the FDA's approval of aducanumab, it's refreshing to learn about a model of Alzheimer's ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback